BIOTRONIK Leaps Forward with Next‑Generation Leadless Pacing
International BIO-LivIQ Study Will Generate Evidence for Global LivIQ Leadless Pacemaker Approvals Far-Field Sensing and AV-Synchronous Pacing Performance Will be Validated by Real World Clinical Data BERLIN, March 24, 2026 /PRNewswire/ -- BIOTRONIK today announced the initiation of its global pivotal study evaluating the LivIQ leadless pacemaker system. This next-generation...
Datasea (NASDAQ: DTSS) Announces Initial U.S. Commercial Rollout and Commercialization Pathway for Acoustic Technology-Enabled Wellness Care Robots
Early-stage deployments across multiple U.S. regions expected to support initial service revenue generation and scalable commercialization model BEIJING, March 24, 2026 /PRNewswire/ -- Datasea Inc. (NASDAQ: DTSS) ("Datasea" or the "Company"), a technology company specializing in acoustic high-tech innovation and AI-driven multimodal digitalization, today announced initial commercial rollout progress in the...
Zocdoc Launches The AI-Informed Patient Report, Revealing How Patient Use of AI Is Reshaping the Patient-Provider Relationship
New findings highlight rising—yet hidden—patient use of AI and surprisingly optimistic providers, pointing to an emerging "triangle of care" NEW YORK, March 24, 2026 /PRNewswire/ -- Zocdoc, the healthcare access infrastructure connecting patients to great care, today released The AI-Informed Patient, a report examining how patients are using AI for medical advice, and...
ZEISS expands ophthalmic workflow portfolio in Canada with enhanced diagnostic, visualization and therapeutic solutions for precision eye care
Expanded treatment and visualization capabilities within posterior care workflows: ICGA for ZEISS CLARUS 700 offers FA + ICG simultaneous capture to help support clinical assessment and streamline the diagnostic process; ZEISS VISULAS green, now available with ZEISS SLT, offers dependable retinal photocoagulation. Ergonomic diagnostic tools support efficient workflows and streamlined examination...
Ping An Good Doctor Reports 2025 Annual Results: Corporate Health Management Business Posts Strong Growth; AI Healthcare Deployment Accelerates
HONG KONG, March 24, 2026 /PRNewswire/ -- Ping An Healthcare and Technology Company Limited ("Ping An Good Doctor" or the "Company"; Stock Code: 1833.HK) announced its annual results for the year ended December 31, 2025. In 2025, the Company recorded total revenue of RMB5.47 billion, up 13.7% year on year; profit attributable to owners of the parent of RMB379.5...
HKeyBio Launches HKEY-NHP-onChip™ 1.1: World’s First NHP In Vitro Model for Autoimmune and Allergic Diseases
The integrated organ-on-chip platform offers 10–100x cost efficiency and 80% reduction in animal use, bridging the gap between preclinical NHP research and human clinical success. SUZHOU, China, SAN FRANCISCO and BOSTON, March 24, 2026 /PRNewswire/ -- HKeyBio, a global leading CRO specializing in preclinical and translational research for autoimmune and allergic diseases, today officially announced the launch of its HKEY-NHP-onChip™ 1.1 platform — the world's first non-human primate (NHP) in vitro model system dedicated to autoimmune and allergic diseases. ...
Discovery Life Sciences and Mindpeak Partner to Bring AI Precision to Cancer Biomarker Testing in Global Clinical Trials
New alliance takes aim at inconsistent biomarker interpretation across pathologists, a persistent challenge in drug development HUNTSVILLE, Ala. and HAMBURG, Germany, March 24, 2026 /PRNewswire/ -- Inconsistent biomarker interpretation across pathologists remains one of the more stubborn challenges in clinical trial development, contributing to variability in patient stratification and eroding confidence in...
Continuity Biosciences and Breakthrough T1D Collaborate to Advance NICHE® Cell-Therapy Platform Toward First-in-Human Study
Collaboration supports IND-enabling development and a planned Phase 1/2a first-in-human clinical study in type 1 diabetes CARY, N.C. and NEW YORK, March 24, 2026 /PRNewswire/ -- Continuity Biosciences and Breakthrough T1D, the leading global type 1 diabetes (T1D) advocacy organization, today announced a strategic collaboration to advance Continuity's NICHE® cell-therapy platform toward...
WuXi Biologics Reports Record 2025 Annual Results
Revenue increased 16.7% YoY to RMB 21.8 billion, and revenue from continuous operations grew over 20% YoY IFRS gross profit margin expanded to 46.0% (+500 bps YoY); adjusted gross profit margin increased to 48.8% (+340bps) EBITDA rose 38.1% YoY and IFRS net profit increased 45.3% YoY; adjusted EBITDA grew 22.8% YoY and adjusted net profit increased 22.0% YoY...
Origin Agritech Names Global Crop Biotechnology Expert Dr. Jian Zhang to Board of Directors; Welcomes Return of Dr. Z. James Chen as Chief Financial Officer
Appointments Reinforce Deep Technical Expertise in Biotech R&D and Capital Markets Leadership as Origin Advances Its Commercial Pipeline BEIJING, March 24, 2026 /PRNewswire/ -- Origin Agritech Ltd. (NASDAQ: SEED) (the "Company" or "Origin"), a leading Chinese agricultural technology company, today announced the appointment of Dr. Jian Zhang as an independent member of its Board of Directors and the reappointment...
